Neuland Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 35.2% CAGR over last 5 years
- Company has a healthy return on capital (ROCE) of 28.2%
- Company has a good return on equity (ROE) track record: 3 Years ROE 22.2%
- Latest quarter profit grew 974.9% YoY, showing strong momentum
- Operating margins have improved to 28.3% from 23.6%
- Company has delivered good sales growth of 16.6% CAGR over last 5 years
CONS
- Receivables are growing faster than sales - a possible quality concern
- Total debt has risen sharply - up 44.6% year on year
- Stock is trading at 8.3x its book value
- Though reporting repeated profits, the company pays out little dividend (12.0%)
- Rich enterprise valuation - EV/EBITDA of 25.3x
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| NEULANDLAB | 23250.30 | 59.93 | 29829.88 | 0.15 | 147.67 | 962.40 | 641.58 | 119.16 | 27.50 | 34.74 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 | |
| 266 | 280 | 272 | 278 | 316 | 250 | 312 | 278 | 258 | 359 | 363 | 469 | 453 | |
| Operating Profit | 97 | 137 | 121 | 107 | 124 | 61 | 86 | 51 | 34 | 155 | 77 | 307 | 189 |
| OPM % | 26.79% | 32.87% | 30.69% | 27.74% | 28.17% | 19.73% | 21.70% | 15.46% | 11.71% | 30.16% | 17.50% | 39.54% | 29.47% |
| 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 | |
| Interest | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before Tax | 84 | 121 | 104 | 92 | 130 | 49 | 128 | 39 | 17 | 129 | 54 | 287 | 198 |
| Tax % | 25.49% | 26.64% | 22.24% | 26.57% | 24.53% | 34.16% | 20.50% | 28.86% | 21.12% | 25.25% | 25.54% | 25.96% | 25.40% |
| Net Profit | 62 | 89 | 81 | 68 | 98 | 32 | 101 | 28 | 14 | 96 | 40 | 213 | 147 |
| 48.50 | 69.42 | 62.90 | 52.70 | 76.65 | 24.91 | 79.03 | 21.62 | 10.68 | 75.18 | 31.50 | 165.65 | 114.86 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 | 2,372 | |
| 473 | 477 | 609 | 661 | 790 | 809 | 920 | 1,097 | 1,155 | 1,450 | 1,644 | |
| Operating Profit | 106 | 50 | 58 | 101 | 146 | 142 | 271 | 462 | 322 | 573 | 728 |
| OPM % | 18.26% | 9.49% | 8.68% | 13.30% | 15.63% | 14.95% | 22.78% | 29.64% | 21.82% | 28.34% | 30.69% |
| 1 | 5 | 3 | 4 | 16 | 2 | 10 | 13 | 97 | 30 | 31 | |
| Interest | 21 | 19 | 16 | 22 | 18 | 13 | 13 | 14 | 8 | 24 | 26 |
| Depreciation | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 92 | 98 |
| Profit before Tax | 67 | 14 | 20 | 52 | 105 | 82 | 215 | 401 | 345 | 488 | 668 |
| Tax % | 30.30% | 12.79% | 18.61% | 69.75% | 23.50% | 22.27% | 24.21% | 25.24% | 24.89% | 25.55% | 25.62% |
| Net Profit | 46 | 12 | 16 | 16 | 80 | 64 | 163 | 300 | 259 | 363 | 497 |
| EPS | 41.58 | 10.59 | 12.83 | 12.38 | 62.58 | 49.52 | 127.14 | 233.51 | 202.20 | 283.01 | — |
| Dividend Payout % | 0.00% | 0.00% | 9.54% | 16.16% | 7.99% | 10.10% | 7.87% | 6.00% | 5.93% | 12.01% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 15%
- 5 Years:
- 17%
- 3 Years:
- 19%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 30%
- 5 Years:
- 35%
- 3 Years:
- 31%
STOCK PRICE CAGR
- 10 Years:
- 37%
- 5 Years:
- 68%
- 3 Years:
- 88%
- 1 Year:
- 61%
RETURN ON EQUITY
- 10 Years:
- 14%
- 5 Years:
- 18%
- 3 Years:
- 22%
- Last Year:
- 21%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| 223 | 235 | 683 | 693 | 769 | 823 | 975 | 1,264 | 1,505 | 1,853 | |
| 192 | 339 | 252 | 285 | 183 | 238 | 125 | 54 | 109 | 261 | |
| Trade Payables | 89 | 129 | 124 | 120 | 157 | 123 | 178 | 199 | 261 | 279 |
| 372 | 359 | 59 | 119 | 202 | 186 | 288 | 302 | 290 | 523 | |
| Total Liabilities | 885 | 1,071 | 1,130 | 1,230 | 1,324 | 1,382 | 1,579 | 1,831 | 2,178 | 2,928 |
| 436 | 445 | 512 | 623 | 697 | 748 | 738 | 805 | 955 | 1,177 | |
| Capital Work in Progress | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 45 | 209 |
| 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 | 2 | |
| 135 | 175 | 193 | 220 | 248 | 265 | 279 | 350 | 386 | 510 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 374 | 316 | 541 | |
| Cash & Bank | 12 | 17 | 37 | 46 | 18 | 19 | 59 | 115 | 257 | 354 |
| 274 | 300 | 276 | 310 | 337 | 326 | 462 | 140 | 111 | 135 | |
| Total Assets | 885 | 1,071 | 1,130 | 1,230 | 1,324 | 1,382 | 1,579 | 1,831 | 2,178 | 2,928 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 55 | 15 | 75 | 61 | 194 | 81 | 282 | 260 | 318 | 348 | |
| Cash from Investing | -42 | -116 | -77 | -49 | -84 | -96 | -61 | -150 | -298 | -424 |
| Cash from Financing | -0 | 105 | 12 | -5 | -114 | 38 | -136 | -69 | 25 | 21 |
| -3 | 0 | 4 | 2 | -9 | 3 | 41 | 41 | 44 | -55 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-09 - Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
2026-09-07 - Neuland Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations'.
2026-08-25 - Neuland Laboratories Limited has informed the Exchange about Credit Rating
2026-08-23 - Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-14 - Neuland Laboratories Limited has informed the Exchange regarding 'Intimation Regarding Completion Of US FDA Inspection'.
2026-08-10 - Transcript of the Earnings Call conducted on August 5, 2026
2026-08-07 - Neuland Laboratories Limited has informed the Exchange about Schedule of meet
2026-08-06 - Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-05 - Audio Recording of the Earnings call conducted on August 5, 2026
News
Recent coverage and analyst commentary for NEULANDLAB
Loading news…
AI Stock Analyst
Neuland Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account